Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Sales and Divestitures: 2020-2022

Historic Gains from Sales and Divestitures for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2022 value amounting to $46,000.

  • Cullinan Therapeutics' Gains from Sales and Divestitures fell 83.27% to $46,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $46,000, marking a year-over-year decrease of 83.27%. This contributed to the annual value of $46,000 for FY2022, which is 83.27% down from last year.
  • As of FY2022, Cullinan Therapeutics' Gains from Sales and Divestitures stood at $46,000, which was down 83.27% from $275,000 recorded in FY2021.
  • In the past 5 years, Cullinan Therapeutics' Gains from Sales and Divestitures registered a high of $275,000 during FY2021, and its lowest value of $46,000 during FY2022.
  • In the last 3 years, Cullinan Therapeutics' Gains from Sales and Divestitures had a median value of $128,358 in 2020 and averaged $149,786.
  • In the last 5 years, Cullinan Therapeutics' Gains from Sales and Divestitures soared by 114.24% in 2021 and then plummeted by 83.27% in 2022.
  • Yearly analysis of 3 years shows Cullinan Therapeutics' Gains from Sales and Divestitures stood at $128,358 in 2020, then spiked by 114.24% to $275,000 in 2021, then slumped by 83.27% to $46,000 in 2022.